Response to CLL Therapies After Fixed-Duration Venetoclax - ASH 2023 Dr. John Seymour

After fixed-duration venetoclax plus rituximab, both BTK inhibitors and retreatment with venetoclax are viable options for treating relapsed chronic lymphocytic leukemia (CLL).
Dr. John Seymour from Peter MacCallum Cancer Center and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting 2023.
Read the full article on CLL Society's website at: cllsociety.org...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society